Abstract：Objective To study the resistance and distribution of imipenem-resistant Pseudomonas aeruginosa
in Western China. Methods A retrospective survey and statistics were carried out on 1459 strains of imipenem
-resistant Pseudomonas aeruginosa infections and drug resistance rates from 2016 to 2017, and the WHONET 5.6
software was used to perform statistical analysis on drug susceptibility results. Results From 2016 to 2017, 7676strains of Pseudomonas aeruginosa were isolated, of which 1,463 strains were resistant to imipenem (19.1%).
Imipenem-resistant Pseudomonas aeruginosa was mainly isolated from sputum specimens, accounting for 72.4% and
74.8% in 2016 and 2017, respectively, followed by urine and secretions. The distribution of departments was mainly
intensive care units, accounting for 17.6% and 18.1% in 2016 and 2017, respectively, followed by neurosurgery and
respiratory departments. As for the characteristics of the age distribution, the number of patients aged 61~70 years
was the highest, with a total of 303 cases (20.7%), which was significantly more than other age groups. The number
of patients aged 10 and under was the lowest, with a total of 36 cases (2.5%). The antimicrobial resistance of 1,463
imipenem-resistant Pseudomonas aeruginosa to 10 commonly used antimicrobial agents was counted. In 2016 and
2017, the resistance rate to amikacin was relatively low, which was 16.3% and 25.7%, respectively, followed by
tobramycin, gentamicin, piperacillin/tazobactam, and ciprofloxacin. The resistance rate to levofloxacin was higher,
which was 43.4% and 45.5%, respectively. Drug resistance rates to commonly used antibiotics in 2018 were higher
than those in 2016. Conclusion Imipenem-resistant Pseudomonas aeruginosa was more common in sputum, and
the isolation rates of the middle-aged and older patients aged 61~70 years were high. The current situation of drug
resistance is severe. Clinical use should be rationally administered under the guidance of antibiotic susceptibility
results. Hospitals should strengthen the management of antibiotics and real-time monitoring of carbapenem-resistant
Pseudomonas aeruginosa infections, and in order to reduce the spread of such drug-resistant bacteria in hospitals.
